Business

mass. movers

Curis stock plunges as drug trial stalls

Curis must provide more safety data to resume testing. Above, a cancer patient gets radiation treatment.

San Antonio Express-News via AP

Curis must provide more safety data to resume testing. Above, a cancer patient gets radiation treatment.

Advertisement

Curis Inc., which is developing cancer therapies, plunged after the Lexington company unveiled quarterly results and an FDA action. Revenue swelled to $7.2 million, from less than $0.6 million a year earlier, and the net loss shrank by nearly half to $1.9 million. But Curis’s cancer drug CUDC-427 was put on partial hold by the FDA — negating any chance of enrolling new patients in a phase 1 study. A patient died of liver failure a month after the end of CUDC-427 treatment.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.